Results 171 to 180 of about 386,415 (318)

GDF15 as a potential biomarker to distinguish fibrotic from non-fibrotic hypersensitivity pneumonitis

Scientific Reports
Hypersensitivity Pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD) characterized by fibrotic HP (fHP) or non-fibrotic HP (non-fHP).
A. Alarcon-Dionet, A. Ruiz, L. Chavez-Galan, I. Buendia-Roldan, M. Selman   +4 more
doaj   +1 more source

Sex Differences in Sleep Profiles and the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Sleep Quality in Adult People with Cystic Fibrosis: A Prospective Observational Study

Diagnostics
Background/Objectives: Recent studies indicate that sleep and sleep disorders differ between men and women, but corresponding data in people with chronic lung diseases are lacking.
Sarah Dietz-Terjung, Svenja Straßburg, Tim Schulte, Paul Dietz, Gerhard Weinreich, Christian Taube, Christoph Schöbel, Matthias Welsner, Sivagurunathan Sutharsan   +8 more
doaj   +1 more source

A joint model for (un)bounded longitudinal markers, competing risks, and recurrent events using patient registry data [PDF]

arXiv
Joint models for longitudinal and survival data have become a popular framework for studying the association between repeatedly measured biomarkers and clinical events. Nevertheless, addressing complex survival data structures, especially handling both recurrent and competing event times within a single model, remains a challenge. This causes important
arxiv  

Coordinate regulation of transforming growth factor beta gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. [PDF]

, 1989
B Raghow, Pati S. Irish, A H Kang
openalex   +1 more source

Peripheral blood gene expression profiling shows prognostic significance for the course of interstitial lung disease in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective We used data from the placebo arm of the SENSCIS trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) with and without mycophenolate mofetil (MMF) treatment ...
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha Visvanathan   +6 more
wiley   +1 more source

Ferruginous bodies and pulmonary fibrosis in dead low to moderately exposed asbestos cement workers: histological examination. [PDF]

, 1987
Leif Johansson, María Albin, Kristina Jakobsson, Hans Welinder, P J Ranstam, Robyn Attewell   +5 more
openalex   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Accepted Article.
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Phenoconversion, a genotype‐phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) and 4‐OH‐solanidine as diet‐derived cytochrome P450 2D6 (CYP2D6) biomarkers in a ...
Jens Andreas Sarömba, Julian Peter Müller, Jolanta Tupiec, Anjali Roeth, Berkan Kurt, Florian Kahles, Thea Laurentius, Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. [PDF]

, 1982
Samuel M. Sobol, Louis Rakita
openalex   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1306-1321, May 2025.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source